Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Phase 2 Results

October 22, 2026

Zealand Pharma Announces Positive Phase 2 ZUPREME-2 Topline Results for Amylin Analog Petrelintide in People with Overweight or Obesity and Type 2 Diabetes

NASDAQ: $ZEAL Copenhagen, Denmark, October 7, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-2 trial… Source: Read More

Clinical Trial

$ZEAL, Amylin Analog Petrelintide, clinical trials, Obesity, Phase 2 Results, Type 2 Diabetes, Zealand Pharma, ZUPREME-2
October 10, 2026

A New Frontier in Metabolic Health: Genentech’s Positive Enicepatide Phase II Results

OTCMKTS: $RHHBY Breakthrough Results in Metabolic Research Genentech, a member of the Roche Group, recently announced promising outcomes from their Phase II clinical trials concerning enicepatide. As the field of metabolic health continues to evolve, this dual-agonist therapeutic represents a significant step forward in addressing weight management and metabolic dysregulation. Understanding the Mechanism Enicepatide is…

Clinical Trial

$RHHBY, clinical trials, Enicepatide, Genentech, GLP-1, Metabolic Health, Phase 2 Results, Roche Group

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

Get FREE Biotech Stock Catalyst Reports

Email